Affimed N.V RSI
Quel est le RSI de Affimed N.V?
Le RSI de Affimed N.V. est 33.48
Quelle est la définition de RSI?
L'indice de force relative (RSI 14) est un indicateur de dynamique qui compare l'ampleur des gains et des pertes sur une période donnée afin de mesurer la vitesse et l'évolution des mouvements de prix d'un titre.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI des entreprises dans Health Care secteur sur NASDAQ par rapport à Affimed N.V
Que fait Affimed N.V?
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Entreprises avec rsi similaire à Affimed N.V
- EDAP TMS S.A a RSI de 33.46
- Danimer Scientific a RSI de 33.46
- Phio Pharmaceuticals a RSI de 33.47
- GoldMining a RSI de 33.47
- STMicroelectronics N.V a RSI de 33.47
- Beluga NV a RSI de 33.47
- Affimed N.V a RSI de 33.48
- RPC a RSI de 33.49
- Zuari Agro Chemicals a RSI de 33.49
- Headwater Exploration a RSI de 33.49
- Goodfood Market a RSI de 33.49
- TKH NV a RSI de 33.49
- Rincon Resources a RSI de 33.49